Skip to main content

The information contained on this global HIPRA website is not intended for audiences in all countries.

General, scientific or technical information about HIPRA products or services is not intended for commercial promotion.

For specific information on the products or services available in your country, please filter by the corresponding country.


BIMERVAX®, emulsion for injection

TriangleBIMERVAX®, COVID-19 adjuvanted recombinant protein vaccine. 


Marketing authorization in the European Union since 30 March 2023 and in the United Kingdom since 31 July 2023.


Update date: 16/10/23





TriangleThis medicine is subject to additional monitoring, which will expedite the detection of new safety information. Healthcare professionals are invited to report suspected adverse reactions.